The British Life Sciences Web Portal
This is a free web portal for the life sciences in the UK and Ireland... » read more
- Cancer Research UK Invests £10m in Personalised Medicine (2017-03-24)
The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK. "I believe we’re on the cusp of making...
- PureTech: Licensing and Equity Agreement with Novartis (2017-03-24)
> Program to initially focus on aging-related disorders > Phase 2b clinical study to commence in 2017 PureTech Health plc (LSE: PRTC), an advanced clinical stage biopharmaceutical company, today announced a licensing and equity agreement with Novartis to ad...
- BioLineRx Acquires Agalimmune to Expand in Immuno-oncology (2017-03-23)
Agalimmune's Lead Asset, AGI-134, Provides a Unique Approach for Eliciting Patient-specific, Anti-tumor Immune Responses in Multiple Cancer Types BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology,...
- UK Biobank, Regeneron & GSK Announce Sequencing Initiative (2017-03-22)
Groundbreaking UK/US Initiative Will Deliver First Data Within a Year Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major research initiative among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate genetic sequence data ...
- Adaptimmune Prices $60.1m Public Offering of ADSs (2017-03-22)
Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 14,300,000 of its American Depositary Shares (“ADSs”) at a price to the public of $4.20 per ADS....
- Pulmocide Ltd Raises $30.4m in Series B Financing Round (2017-03-20)
Pulmocide Ltd, the UK-based drug discovery company developing novel compounds designed for inhaled delivery to treat respiratory syncytial virus (RSV) and pulmonary aspergillosis, today announced the completion of a $30.4 million Series B financing round. The round...
- GSK investiert €162m in neue Impfstoffproduktion in Marburg (2017-03-20)
> Symbolischer Spatenstich für den Neubau einer Antigen-Produktion für Meningokokken-B-Impfstoff in Marburg > GSK investiert 162 Mio € in die Produktion des zukunftsweisenden Impfstoffs als klares Signal für den Standort > GSK unterstreicht erneut sein langfr...
- Eurofins to Invest Millions in New Facility in Scotland (2017-03-17)
Eurofins Scientific (EUFI.PA), a world leader in bioanalytical testing, has announced plans to establish a new pharmaceutical chemistry and microbiology facility in Livingston, Scotland as part of a £4 million investment. The announcement follows Eurofins’ acqui...
- AstraZeneca: Complete Response Letter from FDA for ZS-9 (2017-03-17)
AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ZS-9 (sodium zirconium cyclosilicate). Sodium zirconium cyclosilicate is being developed for the trea...
- AZ & Circassia: Collaboration in Respiratory Disease (2017-03-17)
> Circassia will lead promotion of Tudorza and prepare for potential launch of Duaklir in the US > Strategic collaboration further sharpens AstraZeneca’s respiratory focus on Symbicort, Bevespi Aerosphere, benralizumab and other development programmes Astra...
Life-Sciences-UK.com is your doorway to the British and Irish life sciences!
[LSUK] provides free, up-to-date and structured access to
in the UK and Ireland.
Access is unrestricted and free, requiring no log in and no user registration.The high-quality content is not related to the advertising, with topical relevance being the criterion for inclusion. [LSUK] is 100% Made in Germany!Start here with the latest News!
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)